Glucokinase activators and methods of using same

Patent metadata

Field	Value
Publication number	US-10604541-B2
Application number	US-201716318173-A
Country	US
Kind code	B2
Filing date	Jul 21, 2017
Priority date	Jul 22, 2016
Publication date	Mar 31, 2020
Grant date	Mar 31, 2020

Abstract

A compound, enantiomer, prodrug, diastereomer, or salt is provided which is an activator of the enzyme glucokinase and thus is believed to be useful in as treating diabetes and related diseases, which compound has the structure (I). A method for treating diabetes and related disease employing the compound, enantiomer, prodrug, diastereomer, or salt is also provided.

First claim

What is claimed is:

1. A compound, enantiomer, prodrug, diastereomer, or salt thereof, that is

2. The compound of claim 1 , wherein the compound is a salt of the compound.

3. The compound of claim 1 , wherein the compound is the sodium or potassium salt.

4. The compound of claim 1 , wherein the compound is the sodium salt.

5. The compound of claim 1 , wherein the compound is the potassium salt.

6. The compound of claim 1 that is a crystalline form of said compound.

7. The compound of claim 6 , wherein the crystalline form is the N-1 or P-2 form.

8. The compound of claim 6 , wherein the crystalline form is the N-1 form.

9. The compound of claim 8 , wherein the crystalline form is in substantially pure form.

10. The compound of claim 8 , wherein the crystalline form of the compound is characterized by unit cell parameters substantially equal to the following:
Cell dimensions:
a=8.0531(2)
b=13.5078(3)
c=13.7063(3)
α=73.091(1)
β=88.186(1)
γ=89.881(1)
Space group: P1
Molecules/asymmetric unit (Z′): 2.

11. A compound, enantiomer, diastereomer, or salt thereof, selected from the group consisting of:

12. A pharmaceutical composition comprising a compound as defined in claim 1 or a pharmaceutically-acceptable salt thereof and a pharmaceutically acceptable carrier thereof.

13. A method for treating a disease or disorder comprising administering a therapeutically effective amount of a compound of claim 1 or a pharmaceutically-acceptable salt thereof, to a human patient in need thereof, wherein said disease or disorder is diabetes, hyperglycemia, impaired glucose tolerance, insulin resistance, or hyperinsulinemia.

14. A pharmaceutical composition comprising a compound as defined in claim 4 , wherein said compound is the sodium salt; and a pharmaceutically acceptable carrier thereof.

15. A pharmaceutical composition comprising a compound as defined in claim 5 , wherein said compound is the potassium salt; and a pharmaceutically acceptable carrier thereof.

16. A pharmaceutical composition comprising a compound as defined in claim 8 ; and a pharmaceutically acceptable carrier thereof.

17. The method according to claim 13 , wherein said compound is the crystalline N-1 form.

18. The method according to claim 13 , wherein said compound is the sodium salt.

19. The method according to claim 13 , wherein said compound is the potassium salt.

Assignees

• Bristol Myers Squibb Co

Inventors

• Cheng Peter Tai Wah
• Meng Wei
• Liu Mark
• Wang Bei
• Zhao Rulin

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• C07F9/657181 Primary

  the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative · CPC title

• A61K31/675

  having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate · CPC title

• C07F9/40

  Esters thereof · CPC title